Pharmacogenetics and personalized medicine
DOI:
https://doi.org/10.25758/set.1214Abstract
Pharmacogenetics aims to identify genetic differences between individuals that may influence the response to drug therapy, improving their effectiveness and safety. Associated with pharmacogenetics emerges ‘personalized medicine'. In opposition to the existence of a drug that can treat all patients, the individualized treatment seems the most promising as it reduces the risk of side effects for toxicity (safety), reduces losses due to excess or deficit (dose), avoids the testing methodology in the choice of the correct drug (effectiveness). Pharmacogenetics is relevant to the individual response to the drug in two ways: pharmacokinetics and pharmacodynamics. Genetic variability can affect the way a drug can be absorbed, metabolized, excreted, or activated, and can drive a difference in the patient response. Among the endless number of possible examples, in this review, we present examples related to cytochrome P450 genes, NAT2 gene, and the Cholinesterase gene. Genetic differences between individuals can still affect the response to the drug by its pharmacodynamics, and drug target-specific response to a particular drug. Among the multitude of existing drug targets, it will be presented examples of the G6PD gene and the VKORC1 gene. Despite some evidence given for the benefit of the patient, we are still far from Pharmacogenetics being part of routine clinical practice, perhaps because the cost benefits have not yet been correctly assessed.
Downloads
References
Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-37.
Vermeire S, Van Assche G, Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol. 2010;16(21):2609-15.
Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6(3):162-5.
Silva JC, Soares MA, Martins SO. Reações adversas a medicamentos: análise da base de dados do Sistema Nacional de Farmacovigilância (SVIG), 2009-2011. Lisboa: INFARMED; 2012.
Nussbaum RL, McInnes RR, Willard HF. Thompson & Thompson genetics in medicine. 7th ed. Philadelphia: Saunders/Elsevier; 2007. ISBN 9781416030805
Chang KL, Weitzel K, Schmidt S. Pharmacogenetics: using genetic information to guide drug therapy. Am Fam Physician. 2015;92(7):588-95.
Cravo M, Ferreira P, Sousa P, Moura-Santos P, Velho S, Tavares L, et al. Clinical and genetic factors predicting response to therapy in patients with Crohn’s disease. United Eur Gastroenterol J. 2014;2(1):47-56.
Levano S, Ginz H, Siegemund M, Filipovic M, Voronkov E, Urwyler A, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. Anesthesiology. 2005;102(3):531-5.
Brito M, Tchonhi CL, Santos B, Veiga L. Glucose-6-Phosphate dehydrogenase deficiency in children from 0 to 14 years hospitalized at the Pediatric Hospital David Bernardino, Luanda, Angola. J Pharmacogenomics Pharmacoproteomics. 2014;5(2):1000125.
Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94(4):773-9.
Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
Strachan T, Read A. Human molecular genetics. 4th ed. London: Garland Science; 2010. ISBN 9780815341499
Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983-1013.
Ama T, Bounmythavong S, Blaze J, Weismann M, Marienau MS, Nicholson WT. Implications of pharmacogenomics for anesthesia providers. AANA J. 2010;78(5):393-9.
Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827-31.
Kelly LE, Chaudhry SA, Rieder MJ, ‘t Jong G, Moretti ME, Lausman A, et al. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS One. 2013;8(7):e70073.
Geller F, Soborg B, Koch A, Michelsen SW, Bjorn-Mortensen K, Carstensen L, et al. Determination of NAT2 acetylation status in the Greenlandic population. Arch Toxicol. 2015 Mar 21. doi: 10.1007/s00204-015-1501-1.
Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol. 2013;87(12):2129-39.
Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733-8.
Iohom G, Fitzgerald D, Cunningham AJ. Principles of pharmacogenetics: implications for the anaesthetist. Br J Anaesth. 2004;93(3):440-50.
Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74.
Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, et al. Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study. Lancet Haematol. 2015;2(10):e437-44.
World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO; 2015.
Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33-41.
Militaru FC, Vesa SC, Pop TR, Buzoianu AD. Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015;8(2):171-5.
Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013;58(6):334-8.
Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):135-40.
Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109(6):2477-80.
Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6(3):162-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Saúde e Tecnologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal Saúde & Tecnologia offers immediate free access to its content, following the principle that making scientific knowledge available to the public free of charge provides greater worldwide democratization of knowledge.
The journal Saúde & Tecnologia does not charge authors any submission or article processing charges (APC).
All content is licensed under a Creative Commons CC-BY-NC-ND license. Authors have the right to: reproduce their work in physical or digital form for personal, professional, or teaching use, but not for commercial use (including the sale of the right to access the article); deposit on their website, that of their institution or in a repository an exact copy in electronic format of the article published by Saúde & Tecnologia, provided that reference is made to its publication in Saúde & Tecnologia and its content (including symbols identifying the journal) is not altered; publish in a book of which they are authors or editors the total or partial content of the manuscript, provided that reference is made to its publication in Saúde & Tecnologia.
